Navigation Links
Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Date:5/31/2009

KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer

NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Abstract #4081, entitled, "Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer," is being presented today in a poster during the Gastrointestinal Cancer - Colorectal session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida.

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, patients with 2nd or 3rd line metastatic colon cancer were randomized to receive capecitabine (Xeloda(R)), an approved drug for metastatic colon cancer, at a dose of 825 mg/m2 BID (total daily dose of 1650 mg/m2) on days 1 - 14 every 21 days, plus either perifosine or placebo at 50 mg daily. Treatment was continued until progression. The study enrolled a total of 38 patients, of which 35 patients were evaluable for response (20 patients on the capecitabine + perifosine arm and 15 patients on the capecitabine + placebo arm). The three patients not evaluable for response were all in the capecitabine + placebo arm; 2 patients were inevaluable due to toxicity (days 14, 46) and 1 patient was inevaluable due to a new malignancy on day 6.

The median prior treatment regimens was two, with prior treatment regimens as follows: 91% of the patients r
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... , Sept. 20, 2014 /CNW/ - The issue: Mylan ... recalling all lots of its Mylan-Nitro Spray 0.4 mg/metered dose ... part of the pump component. A missing ... of nitroglycerin to the patient. This defect may lead patients ... they are unable to access it. Not receiving nitroglycerin could ...
(Date:9/19/2014)... CHAPEL HILL, N.C. , Sept. 19, 2014 ... critical role in forging relationships with key opinion ... the market and competition. Despite the critical nature ... has created many challenges, including altering the landscape ... According to research, the oversight ...
(Date:9/19/2014)... -- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... fiduciary duties to shareholders or violated the federal securities ... disclosed: "On September 11, 2014, [PDL] was orally notified ... LLP ("EY"), that it was resigning effective September 11, ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... WOONSOCKET, R.I. , April 26 MultiCell Technologies, Inc. ... European patent (EP 1539819B1) covering certain of its therapeutic candidates for the ... , ... of cancer by several mechanisms.  This regulation can be either ...
... Satori Pharmaceuticals Incorporated , a privately held developer of therapeutics for Alzheimer,s ... of its Board of Directors and the appointment of Jeff Jonker ... , , ... Infinity Pharmaceuticals, recently joined the Satori Board of Directors and has now ...
Cached Medicine Technology:MultiCell Technologies Is Granted European Patent for the Treatment of Cancer 2MultiCell Technologies Is Granted European Patent for the Treatment of Cancer 3Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team 2Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team 3Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team 4Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team 5
(Date:9/21/2014)... Best Cheap Hosting USA, one of the ... and GreenGeeks are the best Reseller hosting suppliers in ... hosting supplier. Actually, these companies have outperformed their competitors ... People can get the best web hosting at affordable ... to the manager, reseller hosting is a very popular ...
(Date:9/21/2014)... 2014 Discount-Dress.com, a company ... recently announced its decision to implement a new shopping ... for ladies across the world. Furthermore, the company has ... ladies. , The new items come in fashionable ... prices, up to 56 percent off. "We are happy ...
(Date:9/21/2014)... Originally approved by the Food and ... propionate) is a synthetic ICS therapy with potent ... treatment of asthma prophylactically in children and adults. ... and HFA, which received the FDA approval in ... propionate, can bind to glucocorticoid receptors with high ...
(Date:9/21/2014)... 2014 Market Research Report ... Industry, 2009-2019 is a professional and in-depth ... (CAS 49562-28-9) industry. The report firstly reviews ... including its classification, application and manufacturing technology.The ... manufacturers of Fenofibrate (CAS 49562-28-9) listing their ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2
... acids help new moms fight depression, according to a new ... Journal. ,"Depression in new mothers is common ... percent of postpartum women. In some high-risk populations, the percentage ... percent. Since depression has devastating effects on both mother and ...
... the home clearly raise the risk of the allergic sensitisation ... older children , however, the influence of the environment at ... This is the conclusion reached by scientists from the GSF ... ,The study published by Chih-Mei Chen et ...
... gay governor, James E. McGreevy appears to be knocking on ... in the news for the right reasons. He has ... ,Former Gov. James E. McGreevy, who was brought up ... religion on Sunday at St. Bartholomew's Church in New York. ...
... of IT students here have developed a device that can enable ... ,Called 'E-Netra', it costs Rs.2,000-3,000 and it reads texts through ... heard through earphones. ,Right now it can only ... in Braille script. ,The Agra College team that took ...
... the information furnished by Indira Gandhi National Open University ... Parliament/State legislature or deemed to be university can ... norms and guidelines laid down by the Distance Education ... meeting held on March 23, 2007 had resolved that ...
... from 105 countries met Friday to formally adopt a 24-page ... global warming after five days of heated debate to reaching ... at 3:30 a.m. Friday," said Carloa Traverso Saibante, information officer ... ,Once the IPCC report is formally adopted, it will ...
Cached Medicine News:Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Climate Talks Reach Consensus in Bangkok 2
The D.O.R.C. CryoStar is the smart cryosurgical system that combines optimal performance with state-of-the-art automation. simple for O.R. staff to operate and maintain throughout every procedure....
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
Red Rubber Robinson Catheters (Latex)...
Silver Foley Catheter 3-way...
Medicine Products: